Land: Australien
Sprog: engelsk
Kilde: APVMA (Australian Pesticides and Veterinary Medicines Authority)
CARPROFEN
ABBEY LABORATORIES PTY LTD
PARENTERAL LIQUID/SOLUTION/SUSPENSION
CARPROFEN ANTI-INFLAMMATORY-NONSTEROIDAL Active 50.0 mg/ml
20mL
VM - Veterinary Medicine
ANALGESIC+MUSCULOSKELETAL
Poison schedule: 4; Withholding period: MEAT WITH HOLDING PERIOD (HORSE): DO NOT USE less than 28 days before slaughter for human consumption.; Host/pest details: CAT: [ANALGESIC, ANTI-INFLAMMATORY AGENT, NON STEROIDAL]; DOG: [ANALGESIC, ANTI-INFLAMMATORY AGENT, NON STEROIDAL]; HORSE: [ANALGESIC, ANTI-INFLAMMATORY AGENT, NON STEROIDAL]
Registered
2023-07-01
CarproMax INJECTION 91746/133351 Product Name: APVMA Approval No: Label Name: CarproMax INJECTION Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Constituent Statements: 50 mg/mL CARPROFEN Claims: CarproMax injection is a non-steroidal, anti-inflammatory formulation with analgesic action. It is indicated as an aid in the alleviation of pain and inflammation associated with musculoskeletal disorders and for anti-inflammatory treatment after surgery in the horse. In the dog and cat, it is indicated for the control of post-operative pain and inflammation following orthopaedic and soft tissue (including intra-ocular) surgery. Net Contents: 20 mL Directions for Use: Restraints: DO NOT administer by intramuscular injection. DO NOT exceed the recommended dose or duration of treatment. DO NOT administer other NSAID’s concurrently or within 24 hours of each other. Some NSAID’s may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects. DO NOT use in any animal less than 6 weeks of age, or in aged animals. Contraindications: Contraindicated in animals suffering from cardiac, hepatic, or renal disease, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. RLP APPROVED Precautions: Where there is a possibility of gastro-intestinal ulceration or bleeding, use may involve additional risk. If such a use cannot be avoided, animals may require a reduced dosage and careful clinical management. Concurrent administration of potential nephrotoxic drugs should be avoided. In the absence of any specific studies in pregnant target animals, such use is not indicated. NSAID’s can cause inhibition of phagocytosis and hence, in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. Side Effe Læs hele dokumentet